1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

Technology appraisal guidance [TA96] Published date: 22 February 2006

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Related NICE guidance
  • 9 Review of guidance
  • Appendix A. Appraisal Committee members and NICE project team
  • Appendix B. Sources of evidence considered by the Committee
  • Appendix C. Detail on criteria for audit of the use of adefovir dipivoxil and peginterferon alfa-2a for chronic hepatitis B
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

Changes after publication

Changes after publication

March 2014: implementation section updated to clarify that adefovir dipivoxil and peginterferon alfa-2a are recommended as options for treating chronic hepatitis B. Additional minor maintenance update also carried out.

June 2013: Recommendations 1.2–1.4 replaced by recommendations 1.5.13–1.5.15 in Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults (NICE clinical guideline 165).

March 2012: minor maintenance


  • Next